Back to
New collaboration makes further 100 million doses of COVID-19 vaccine available to low- and middle-income countries
-
Collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation will accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines, if proven to be safe and effective, for low- and middle-income countries in 2021
-
The expansion follows August’s announcement of up to 100 million doses to be delivered by the collaboration, bringing the total now to be delivered by the partnership to up to 200 million doses of COVID-19 vaccines, priced at a maximum of US$ 3 per dose, with an option to secure more
-
Dr Seth Berkley: “This is vaccine manufacturing for the Global South, by the Global South, helping us to ensure no country is left behind when it comes to the race for a COVID-19 vaccine”
Geneva, 29 September 2020 – A further collaboration among the Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, Gavi and the Bill & Melinda Gates Foundation will accelerate the manufacture and delivery of up to an additional 100 million doses of safe and effective COVID-19 vaccines for low- and middle-income countries (LMICs) as part of the Gavi COVAX AMC, a mechanism within the COVAX Facility.
This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement announced in August. This arrangement again provides an option to secure additional doses, potentially several times the 200 million dose total, if the COVAX Facility sees a need for it.
The collaboration will provide upfront capital to SII to help it increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO Prequalification, doses can be distributed at scale to LMICs as part of the Gavi COVAX AMC mechanism as early as the first half of 2021.
“This is vaccine manufacturing for the Global South, by the Global South, helping us to ensure no country is left behind when it comes to access to a COVID-19 vaccine,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “The momentum behind our effort to ensure global, equitable access to COVID-19 vaccines is really building. Last week we were able to announce the historic number of countries that are now signed up to the COVAX Facility, today we can announce further doses of safe, effective vaccines that will be reserved specifically for low- and middle-income countries. No country, rich or poor, should be left at the back of the queue when it comes to COVID-19 vaccines; this collaboration brings us another step closer to achieving this goal.”
The funding will help accelerate the manufacturing by SII for candidate vaccines licensed from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification. The vaccines will have a ceiling price of US$3 per dose, a price enabled by investments made by partners such as the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation and SII.
“The collaboration further bolsters our fight against COVID-19! Through the avid support of Gavi and the Bill & Melinda Gates Foundation, we will now manufacture and deliver up to an additional 100 million doses of immunogenic and safe-proven future COVID-19 vaccines to India and low- and middle-income countries in 2021,” said Adar Poonawalla, CEO of Serum Institute of India “At this stage, It is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest parts of the world providing full immunization coverage in a bid to contain the spread of the pandemic.”
The Gavi COVAX AMC, which is currently seeking at least US$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine doses. The Gavi Board has agreed upon the final list of 92 countries that will be supported by the Gavi COVAX AMC. Under the new collaboration, AstraZeneca’s candidate vaccine, if successful, will be available to 61 AMC-eligible countries. Novavax’s candidate, if successful, will be available to all 92 countries supported by the Gavi COVAX AMC. These countries align with SII’s licensing agreements with the two partners.
“This collaborative effort shows the capacity of the Access to COVID-19 Tools (ACT) Accelerator to bring together diverse partners to ensure a fair and effective response to this global crisis,” said Mark Suzman, CEO of the Bill & Melinda Gates Foundation.
The collaboration between Gavi, SII, and the Gates Foundation supports the efforts of the ACT Accelerator's vaccines pillar, also known as COVAX, co-led by Gavi, CEPI and the World Health Organization (WHO), to accelerate the development of COVID-19 vaccines and ensure rapid, global access to them. Decisions around investment in manufacturing are taken in close collaboration between these three lead organisations of the COVAX pillar.
Under the COVAX umbrella, Gavi is coordinating the COVAX Facility, which provides governments with the opportunity to benefit from a large portfolio of COVID-19 candidate vaccines using a range of technology platforms, produced by more manufacturers across the world, with a bigger market to provide security of demand.
So far 75 higher-income economies have formally committed to join the Facility, in addition to the 92 low- and middle-income economies that are eligible for support from the Gavi COVAX AMC.
The Bill & Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further US$150 million to Gavi, bringing the total funding provided through this collaboration to US$300 million. This will be used to support the Serum Institute of India to manufacture potential vaccine candidates, and for future procurement of vaccines for low- and middle-income countries via Gavi’s COVAX AMC.
The deal is additional to a Memorandum of Understanding between AstraZeneca and Gavi, announced in June, which will commit an additional 300 million doses of AstraZeneca’s candidate vaccine to the wider COVAX Facility, to be supplied upon licensure or prequalification. These two deals can help assure access to early doses for the most vulnerable on a truly global scale.
Media Contacts
James Fulker, Gavi
Phone: +41 79 429 55 05
Email: jfulker@gavi.org
Related content
COVAX and World Bank to Accelerate Vaccine Access for Developing Countries
COVAX and the World Bank will accelerate COVID-19 vaccine supply for developing countries through a new financing mechanism that builds on Gavi’s newly designed AMC cost-sharing arrangement. This allows AMC countries to purchase doses beyond the…
First doses donated by Japan to COVAX reach lower-income countries
The first COVID-19 vaccine doses donated by Japan to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC) have been shipped, with first shipments set to arrive in Cambodia and Iran on Friday, 23 July, and Bangladesh on Saturday, 24 July.
16 July 2021 – Following close collaboration between the African Union (AU)/ African Vaccine Acquisition Trust (AVAT), COVAX and the United States Government, AU Member States are set to receive approximately 25 million COVID-19 vaccines to…
Gavi signs agreements with Sinopharm and Sinovac for immediate supply to COVAX
Gavi, the Vaccine Alliance announced today that it had signed advance purchase agreements (APAs) with Sinopharm for its “BBIBP-CorV” inactivated virus vaccine against COVID-19 as well as with Sinovac for its inactivated virus vaccine against…
6 million children benefitting from the first ever multi-antigen vaccination campaign
UNICEF, Gavi, the Vaccine Alliance and WHO have partnered with the Ministry of Health and Child Care to launch a new vaccine campaign introducing typhoid conjugate vaccine into the routine immunisation schedule across Zimbabwe.
Joint COVAX Statement on the equal recognition of vaccines
Geneva/New York/Oslo, 01 July 2021 – COVAX was built on the principle of equitable access to COVID-19 vaccines to protect the health of people all across the globe. That means protecting their lives and livelihoods, including their ability to…
Indonesia introduces Pneumococcal Conjugate Vaccine (PCV) across the country
Jakarta/Geneva, 30 June 2021 – Up to 4.5 million children across Indonesia will be protected against the most common cause of severe pneumonia every year, after the introduction of Pneumococcal Conjugate Vaccine (PCV) into the country’s routine…
Gavi signs agreement with Clover Biopharmaceuticals for supply to COVAX
Geneva, 30 June 2021 – Gavi, the Vaccine Alliance announced today that it had signed an advance purchase agreement (APA) with Clover Biopharmaceuticals for its SCB-2019 protein-based adjuvanted vaccine candidate against COVID-19. The agreement…
US-donated vaccine deliveries through COVAX set to begin, with first shipment to Honduras
Geneva, 27 June 2021 – Following announcements in recent weeks of donation pledges by the Biden-Harris Administration, COVAX is preparing to ship doses of COVID-19 vaccines donated to COVAX by the United States Government to protect at-risk…
Geneva, 25 June 2021 – The Board of Gavi, the Vaccine Alliance has made several decisions to strengthen the organisation’s commitment to protecting the most vulnerable everywhere – through routine immunisation, access to COVID-19 vaccines via the…
Geneva, 24 June 2021 – Global health leaders Gavi, the Vaccine Alliance and the Global Fund to Fight AIDS, Tuberculosis and Malaria have joined forces with the International Federation of Accountants (IFAC) to contribute to, and support, the…
What does COVAX’s latest supply forecast tell us?
The forecast is encouraging given the supply disruptions COVAX and countries with bilateral deals are currently experiencing, and the general challenges manufacturers are experiencing as they ramp up supply at historic speed and scale.
Gavi allocates US$ 60 million for RBC GAM impact investment bond
Gavi is investing in the RBC Global Asset Management’s RBC Impact Bond Strategy, which supports measurable social and environmental progress.
The Republic of Korea has announced a pledge of US$ 200 million to the Gavi COVAX Advance Commitment (Gavi COVAX AMC), with US$ 100 million to be provided in 2021 and an additional US$ 100 million to be provided in 2022
COVAX welcomes dose sharing commitments for 870 million additional doses to support equitable access to vaccines in 2021 and 2022, with the aim to deliver at least half by the end of 2021.
Gavi welcomes U.S. decision to procure 500 million vaccine doses to be delivered through COVAX
Geneva, 10 June 2021 – Gavi, the Vaccine Alliance, today welcomes the decision by the United States Government to procure 500 million COVID-19 vaccine doses on behalf of the COVAX Facility.
Gavi, the Vaccine Alliance, welcomes the announcement by the United States Government of its strategy for global vaccine sharing, which sets out how it will provide at least 80 million doses of vaccines to the rest of the world – with the…
World leaders unite to commit to global equitable access for COVID-19 vaccines
The Gavi COVAX AMC Summit “One World Protected” virtual event, hosted today by the Government of Japan and Gavi, the Vaccine Alliance, raised US$ 2.4 billion from nearly 40 donor governments, the private sector and foundations, exceeding the…
New Zealand transfers vaccine doses to COVAX – 6 Pacific nations first to benefit
Responding to an urgent need for doses around the world, the Government of New Zealand has pledged to transfer 1.6 million doses allocated through COVAX to lower-income economies.
Call to action to equip COVAX to deliver 2 billion doses in 2021
Countries that are advanced in their vaccination programmes are seeing cases of COVID-19 decline, hospitalisations decrease and early signs of some kind of normality resume. However, the global picture is far more concerning.
Global leaders renew their commitment to address urgency of COVID-19 pandemic
At today’s Global Health Summit, hosted by the European Commission and Italy as chair of the G20, leaders pledged their support to the Gavi COVAX Advance Market Commitment (AMC).
Gavi signs agreement with Johnson & Johnson for supply of its COVID-19 vaccine to COVAX
The signed advance purchase agreement (APA) is for a commitment to purchase 200 million doses of the Johnson & Johnson vaccine, with the goal of them being made available to the COVAX Facility in 2021.
Individuals can now directly fund vaccines for lower-income countries via the Gavi COVAX AMC to help end the pandemic. The platform will give businesses a chance to match employee and customer contributions.
Japan to host Gavi's COVAX Advance Market Commitment (AMC) Summit
Geneva, 12 May 2021 – The Government of Japan yesterday announced that it will host the virtual Gavi COVAX Advance Market Commitment (AMC) Summit on June 2nd 2021. The event, co-hosted by Japanese Prime Minister H.E.
The pledges were announced at Global Citizen’s Vax Live Concert on Saturday, co-hosted by Selena Gomez and featuring messages from Prince Harry, the Duke of Sussex, His Holiness Pope Francis and several Heads of State
Gavi signs agreement with Novavax to secure doses on behalf of COVAX Facility
The signed advance purchase agreement (APA) is for a commitment to purchase 350 million doses of the Novavax vaccine candidate. Deliveries will commence in Q3 2021, upon regulatory approval.
Gavi signs agreement with Moderna to secure doses on behalf of COVAX Facility
The signed advance purchase agreement (APA) is for up to 500 million doses of the COVID-19 vaccine manufactured by Moderna. Supply via the agreement will take place from the second half of 2021 through 2022, with options in place to address the…
Geneva/New York, 26 April 2021 – While immunization services have started to recover from disruptions caused by COVID-19, millions of children remain vulnerable to deadly diseases, the World Health Organization (WHO), UNICEF and Gavi, the Vaccine…
France makes important vaccine dose donation to COVAX
Today, to mark the first year of the creation of the Access to COVID-19 Tools (ACT) Accelerator, President Emmanuel Macron announced that France has begun sharing vaccine doses with COVAX, starting with a first batch of 105,600 doses – with 500,…
Global leaders rally to accelerate access to COVID-19 vaccines for lower-income countries
The “One World Protected” Event, hosted today by the United States and Gavi, the Vaccine Alliance, launched a campaign to raise US$ 2 billion for the global fight against COVID-19.
COVAX reaches over 100 economies, 42 days after first international delivery
The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on February 24th.
Gavi and Save the Children form global partnership to immunise zero-dose and vulnerable children
The partnership will focus on reaching children who are currently receiving no routine vaccines and marginalised communities in line with Gavi’s vision to ‘leave no-one behind with immunisation’.
United States to host launch event for Gavi COVAX AMC 2021 investment opportunity
The virtual event will bring together world leaders, the private sector, civil society, and key technical partners to galvanize resources and commitment to the Gavi COVAX Advance Market Commitment (AMC).
The COVAX Facility has notified participating economies that deliveries of doses from the Serum Institute of India (SII) will be delayed in March and April.
A new partnership between three donor agencies jointly offers an updated version of the Strategic Training Executive Programme, known as STEP 2.0.
COVAX publishes first round of allocations
Geneva/Oslo/New York, 2 March 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO), as co-leads of the COVAX initiative for equitable global access to COVID-…
First COVID-19 COVAX vaccine doses administered in Africa
Today, the governments of Côte d’Ivoire and Ghana began COVID-19 vaccination campaigns aimed at protecting healthcare workers
COVAX announces 600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries to Abidjan, Cote d’Ivoire are expected this week.
No-fault compensation programme for COVID-19 vaccines is a world first
New programme makes compensation available to eligible individuals in 92 low- and middle-income countries without need to resort to law courts.
Today G7 leaders announced a doubling of funding for Gavi COVAX AMC to support lower-income economies obtain life-saving vaccines against COVID-19, ensuring greater equity in fighting to end the acute phase of the pandemic.
Gavi signs memorandum of understanding with Novavax on behalf of COVAX Facility
The signed memorandum of understanding (MoU) between Gavi and Novavax is to make a cumulative volume of 1.1 billion doses of the Novavax vaccine candidate available to the COVAX Facility.
COVAX Statement on WHO Emergency Use Listing for AstraZeneca/Oxford COVID-19 Vaccine
Geneva / New York / Oslo – 15 February 2021 The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organisation (WHO), as co-leads of the COVAX initiative for equitable global access to…
COVAX Statement on New Variants of SARS-CoV-2
The emergence of variants of SARS-CoV-2, the virus that causes COVID-19, serve as a powerful reminder that viruses by their very nature mutate, and that the scientific response may need to adapt if they are to remain effective against them.
COVAX publishes first interim distribution forecast
Geneva/Oslo/New York, 3 February 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the World Health Organisation, as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines…
COVAX announces new agreement, plans for first deliveries
COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements.
500,000 doses of Ebola vaccine to be made available to countries for outbreak response
A Gavi-funded global emergency stockpile of Ebola vaccines will be accessible to all countries following a procurement process concluded by UNICEF
The United States has approved US$ 4 billion for Gavi, the Vaccine Alliance to ensure lower-income economies have equitable access to safe and effective COVID-19 vaccines on the same urgent timeline as wealthier countries.
COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors.
Gavi Board approves new push to reach unvaccinated children worldwide
Gavi Board approves more than US$ 600 million in new funding to help accelerate efforts to reach ‘zero-dose’ and under-immunised children in the face of the COVID-19 pandemic.
High-risk and vulnerable groups and healthcare workers first in line for successful vaccine.
Gavi and IOM join forces to improve immunisation coverage for migrants
Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world
Gavi statement on AstraZeneca/Oxford interim efficacy data
Geneva, 24 November 2020 – Gavi, the Vaccine Alliance, as co-lead of COVAX and administrator of the COVAX Facility, welcomes the release of interim efficacy data for the AstraZeneca/Oxford COVID-19 vaccine candidate.
COVAX Facility convenes first meeting of COVAX AMC engagement group
The COVAX AMC Engagement Group, composed of Gavi COVAX AMC participants, donors, and other stakeholders, forms a key component of Facility governance.
The European Commission, France, Spain, The Republic of Korea and the Bill & Melinda Gates Foundation pledge US$ 360 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)
COVAX Facility convenes first meeting of COVAX Shareholders Council
The COVAX Shareholders Council, composed of all self-financing participants, forms a key component of Facility governance.
COVAX welcomes appointment of civil society representatives
As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, CEPI, and the WHO – welcomes the appointment of civil society organisation representatives to…
Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility.
Myanmar introduces cervical cancer vaccine nationally, despite COVID-19 challenges
Around 450,000 girls aged 9-10 will receive the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. Myanmar currently has the second-highest incidence of cervical cancer in Southeast Asia.
Japan pledges US$ 130 million to support global access to COVID-19 vaccines
Japanese Government pledges US$ 130 million in funding to the Gavi COVAX Advance Market Commitment (AMC), bringing the total raised to roughly US$ 1.8 billion.
Countries pledge nearly US$ 1 billion to support equitable access to COVID-19 vaccines
The United Kingdom, Canada, Germany, Italy and Sweden pledge approximately US$ 960 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)
The Gavi Board has approved the provision of US$ 150 million in initial funding to jumpstart support COVAX AMC-eligible countries’ readiness to deliver COVID-19 vaccines, in the form of planning, technical assistance and cold chain equipment
Collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation will accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines, if proven to be…
José Manuel Barroso named as new Chair of the Gavi Board
Gavi Board unanimously approves the selection of former Prime Minister of Portugal and President of the European Commission José Manuel Barroso as its new Chair
Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX Facility
64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days
Australia commits AU$ 80 million to guarantee access to COVID-19 vaccines for all
The funding will support the Gavi COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations
172 countries & multiple candidate vaccines engaged in COVID-19 Vaccine Global Access Facility
Goal of bringing the pandemic under control via equitable access to COVID-19 vaccines needs urgent, broadscale commitment and investment from countries
CSOs will play a vital role in the development and implementation of the COVAX initiative as well as the deployment of any successful vaccine through COVAX.
New landmark collaboration between the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of future safe and effective COVID-…
Gavi Board agrees scope of COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations.
Gavi helps immunise 65 million children in 2019, though COVID-19 puts progress under pressure
New analysis of WHO/UNICEF data by Gavi, the Vaccine Alliance, shows the gap in vaccine coverage between Gavi-supported lower-income countries and wealthier countries has shrunk to record lows
More than 150 countries engaged in COVID-19 vaccine global access facility
Seventy-five countries submit expressions of interest to COVAX Facility, joining up to 90 further countries which could be supported by the COVAX Advance Market Commitment (AMC)
Global technology company TransferWise and a donor which asked to remain anonymous made significant financial commitments to Gavi’s Advance Market Commitment for COVID-19 Vaccines (Gavi COVAX AMC)
Gavi Board calls for global access to COVID-19 vaccines
Gavi Board shows support for continued work on COVAX Facility: a global, coordinated mechanism designed to ensure rapid and equitable access to safe and efficacious COVID-19 vaccines to as broad a global population as possible
First-of-its-kind vaccine agreement helps end Ebola outbreak in eastern DRC
DRC government and WHO declare over the long-running Ebola outbreak in North Kivu, South Kivu and Ituri provinces after more than 50 days without a case.
Gavi a top performer in leading transparency index
The Vaccine Alliance ranked in the highest ‘Very good’ category out of 47 international development organisations assessed in the 2020 Aid Transparency Index
DRC recognised for its immunisation efforts
The Government of the Democratic Republic of the Congo is doubling its vaccine funding
New supply agreement between UNICEF and Serum Institute of India (SII) makes pneumococcal conjugate vaccine (PCV) available at US$2.00 per dose, a 43% reduction from the Gavi price at the start of the AMC
World leaders make historic commitments to provide equal access to vaccines for all
The Global Vaccine Summit, hosted by the UK, raises US$ 8.8 billion from 32 donor governments and 12 foundations, corporations and organisations to immunise 300m children and support the global fight against COVID-19.
Gavi launches innovative financing mechanism for access to COVID-19 vaccines
Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC) launched at Global Vaccine Summit 2020 draws strong support, early commitments from global leaders.
On the eve of the Global Vaccine Summit 2020, five manufacturers commit to increasing and prioritising HPV vaccine supply to Gavi-supported countries, which have among the highest cervical cancer burdens in the world.
Private sector partners strengthen Gavi programmes with more than US$ 70 million in contributions
The commitments build on the potency of public private partnerships, which have contributed to Gavi’s success.
Switzerland commits CHF 30 million to Gavi
Contribution will go towards Gavi’s efforts to deliver life-saving vaccines to children in the world’s poorest countries in 2021-2025 strategic period.
Italy deepens support for Gavi with €150 million IFFIm pledge
Pledge follows €120 million in direct funding to Gavi Italy announced at last month’s Coronavirus Global Response pledging conference.
Gavi receives US$ 5 million from The Rockefeller Foundation
Gavi receives US$ 5 million from the Rockefeller Foundation to support health workers facing COVID-19 pandemic
The UPS Foundation commits US$ 3 million to Gavi
UPS partnership with Gavi builds on successful efforts to expand and improve vaccine delivery in Uganda and some of the world’s most underserved communities.
New donor Greece pledges €1.5 million to Gavi COVID response
New funding for Gavi to support lower-income countries’ response to the COVID-19 pandemic, including supporting health systems.
New Zealand announces NZ$ 7 million pledge to Vaccine Alliance
Funding will support the response to the COVID-19 pandemic in lower-income countries as well as the vaccination of thousands of children in vulnerable Pacific nations.
Agencies call for joint effort to safely deliver routine immunization and proceed with vaccination campaigns against deadly vaccine-preventable diseases.
Canada commits CAD 600 million to Gavi
Canada’s contribution will go towards Gavi’s efforts to deliver life-saving vaccines to children in the world’s poorest countries in 2021-2025 strategic period.
Spain pledges new support to Gavi
Funding will help immunise 300 million children over the next five years, saving up to 8 million lives, as well as support universal access to COVID-19 vaccines.
Italy pledges new support to Gavi
Funding will help immunise 300 million children over the next five years, saving up to 8 million lives, as well as support universal access to COVID-19 vaccines.
Countries pledge new support to Gavi
The funding will help immunise 300 million children over the next five years, saving up to 8 million lives, as well as support universal access to COVID-19 vaccines.
Norway increases commitment to immunisation for the most vulnerable, pledges USD 1 billion to Gavi
Funding will help Gavi protect the most vulnerable, particularly children, against a range of infectious diseases.
Gavi welcomes UK funding pledge
Funding will support Gavi’s response to COVID-19 along with efforts to vaccinate 300 million children across the developing world, saving up to 8 million lives.
Gavi welcomes US$ 10 million contribution from TikTok
Short video platform pledges to support Gavi’s life-saving immunisation programmes and future deployment of COVID-19 vaccines.
COVID-19: Gavi and UNICEF to secure equipment and diagnostics for lower-income countries
As part of Gavi’s work supporting lower-income countries’ response to COVID-19, the Alliance is providing US$ 40 million to UNICEF to secure supplies of personal protective equipment (PPE) and diagnostics for 58 countries.
Gavi and global health actors collaborate to accelerate COVID-19 technologies for all
Goal of new global collaboration is to make COVID-19 diagnostics, therapeutics and vaccines available to everybody that needs them as quickly as possible.
Saudi Arabia pledges US$ 150 million to Gavi COVID response
Pledge follows G20 commitment to provide immediate resources to Gavi.
Reed Hastings and Patty Quillin support Gavi with US$ 30 million donation
Cash donation supports the Alliance’s response to COVID-19 and helps protect the world against new outbreaks of other infectious diseases.
COVID-19: massive impact on lower-income countries threatens more disease outbreaks
At least 13.5 million people to miss out on vaccinations due to postponement of campaigns and interruptions in routine vaccinations, with millions more likely to follow.
With senior health officials setting the annual direction for the World Health Organization this week, multiple health challenges and considerations vie for attention amidst a packed agenda. Find out how Gavi helps ensure that immunisation is…
Study: vaccines prevent not just disease, but also poverty
New study shows that immunisation in the world’s poorest countries is set to save millions from one of the primary causes of extreme poverty: health expenses
Ebola vaccine purchasing commitment from Gavi to prepare for future outbreaks
Agreement will help push vaccine towards regulatory approval.
World leaders make record-breaking commitment to protect poorest children with vaccines
Support puts Gavi, the Vaccine Alliance on the path to immunise a further 300 million children and save up to 6 million more lives.
Gavi commits to purchasing Ebola vaccine for affected countries
Vaccine Alliance ready to begin procurement as soon as WHO recommends a vaccine for use.
Five nations and the Bill and Melinda Gates Foundation launch Advance Market Commitment for vaccines
With an additional US $1 billion per year immunization could save ten million more lives in a decade
Prime Minister of India calls on world leaders to embrace vaccines as key to saving children's lives